William D. Waddill Senior Vice President and Chief Financial Officer
Will Waddill joined OncoMed Pharmaceuticals as Senior Vice President, Chief Financial Officer in October, 2007. He began his career 30 years ago in commercial banking and public accounting and has been in the biotechnology industry for 20 years. Prior to joining OncoMed, Mr. Waddill was Senior Vice President, CFO at Ilypsa, where he was responsible for all corporate financial matters, most notably the strategic financial evaluation and implementation of a plan that led to a $420 million acquisition by Amgen in 2007. Prior to his work at Ilypsa, he served as the founder and principal at Square One Finance, a financial consulting business, managing the finances of 33 start-up biotechnology companies, including eight that became public and six that have been acquired. Prior, Mr. Waddill held positions at Exelixis, most recently as Senior Director, Finance and Administration, and served as CFO of Medical Science Partners, a venture capital firm in Boston. Mr. Waddill serves on the board of the Association of Bioscience Financial Officers, is Co-chair of the Biotechnology Industry Organization (BIO) Finance and Tax Committee, and is Chairman of the BIO Business Solutions Advisory Board. He received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhouseCoopers and Deloitte.